Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

por Park, Keunchil, Tan, Daniel Shao Weng, Su, Wu-Chou, Cho, Byoung Chul, Kim, Sang-We, Lee, Ki Hyeong, Wang, Chin-Chou, Seto, Takashi, Huang, Dennis Chin-Lun, Jung, Helen Hayoun, Hsu, Ming-Chi, Bogenrieder, Thomas, Lin, Chia-Chi
Publicado 2021